Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 234

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials

Open access
Stewart, Lesley A, Simmonds, Mark, Duley, Lelia, Llewellyn, Alexis, Sharif, Sahar, Walker, Ruth AE, Beresford, Lucy, Wright, Kath, Aboulghar, Mona M, Alfirevic, Zarko, Azargoon, Azam, Bagga, Rashmi, Bahrami, Elham, Blackwell, Sean C, Caritis, Steve N, Combs, C Andrew, Croswell, Jennifer M, Crowther, Caroline A, Das, Anita F, Dickersin, Kay, Dietz, Kristina C, Elimian, Andrew, Grobman, William A, Hodkinson, Alexander, Maurel, Kimberley A, McKenna, David S, Mol, Ben W, Moley, Kelle, Mueller, Jamie, Nassar, Anwar, Norman, Jane E, Norrie, John, O'Brien, John M, Porcher, Raphael, Rajaram, Shalini, Rode, Line, Rouse, Dwight J, Sakala, Carol, Schuit, Ewoud, Senat, Marie-Victoire, Sharif, Sahar, Simmonds, Mark, Simpson, Joe L, Smith, Katherine, Tabor, Anne, Thom, Elizabeth A, van Os, Melanie A, Whitlock, Evelyn P, Wood, Stephen, Walley, Tom · 2021 · The Lancet

Abstract

BACKGROUND: Preterm birth is a global health priority. Using a progestogen during high-risk pregnancy could reduce preterm birth and adverse neonatal outcomes. METHODS: We did a systematic review of randomised trials comparing vaginal progesterone, intramuscular 17-hydroxyprogesterone caproate (17-OHPC), or oral progesterone with control, or with each other, in asymptomatic women at risk of preterm birth. We identified published and unpublished trials that completed primary data collection before July 30, 2016, (12 months before data collection began), by searching MEDLINE, Embase, CINAHL, the Maternity and Infant Care Database, and relevant trial registers between inception and July 30, 2019. Trials of progestogen to prevent early miscarriage or immediately-threatened preterm birth were excluded. Individual participant data were requested from investigators of eligible trials. Outcomes included preterm birth, early preterm birth, and mid-trimester birth. Adverse neonatal sequelae associated with early births were assessed using a composite of serious neonatal complications, and individually. Adverse maternal outcomes were investigated as a composite and individually. Individual participant data were checked and risk of bias assessed independently by two researchers. Primary meta-analyses used one-stage generalised linear mixed models that incorporated random effects to allow for heterogeneity across trials. This meta-analysis is registered with PROSPERO, CRD42017068299. FINDINGS: Initial searches identified 47 eligible trials. Individual participant data were available for 30 of these trials. An additional trial was later included in a targeted update. Data were therefore available from a total of 31 trials (11 644 women and 16185 offspring). Trials in singleton pregnancies included mostly women with previous spontaneous preterm birth or short cervix. Preterm birth before 34 weeks was reduced in such women who received vaginal progesterone (nine trials, 3769 women; relative risk [RR] 0·78, 95% CI 0·68-0·90), 17-OHPC (five trials, 3053 women; 0·83, 0·68-1·01), and oral progesterone (two trials, 181 women; 0·60, 0·40-0·90). Results for other birth and neonatal outcomes were consistently favourable, but less certain. A possible increase in maternal complications was suggested, but this was uncertain. We identified no consistent evidence of treatment interaction with any participant characteristics examined, although analyses within subpopulations questioned efficacy in women who did not have a short cervix. Trials in multifetal pregnancies mostly included women without additional risk factors. For twins, vaginal progesterone did not reduce preterm birth before 34 weeks (eight trials, 2046 women: RR 1·01, 95% CI 0·84-1·20) nor did 17-OHPC for twins or triplets (eight trials, 2253 women: 1·04, 0·92-1·18). Preterm premature rupture of membranes was increased with 17-OHPC exposure in multifetal gestations (rupture <34 weeks RR 1·59, 95% CI 1·15-2·22), but we found no consistent evidence of benefit or harm for other outcomes with either vaginal progesterone or 17-OHPC. INTERPRETATION: Vaginal progesterone and 17-OHPC both reduced birth before 34 weeks' gestation in high-risk singleton pregnancies. Given increased underlying risk, absolute risk reduction is greater for women with a short cervix, hence treatment might be most useful for these women. Evidence for oral progesterone is insufficient to support its use. Shared decision making with woman with high-risk singleton pregnancies should discuss an individual's risk, potential benefits, harms and practicalities of intervention. Treatment of unselected multifetal pregnancies with a progestogen is not supported by the evidence. FUNDING: Patient-Centered Outcomes Research Institute.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(21)00217-8

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 234

Metadata

Authors
Stewart, L. A., Simmonds, M., Duley, L., Llewellyn, A., Sharif, S., Walker, R. A., Beresford, L., Wright, K., Aboulghar, M. M., Alfirevic, Z., Azargoon, A., Bagga, R., Bahrami, E., Blackwell, S. C., Caritis, S. N., Combs, C. A., Croswell, J. M., Crowther, C. A., Das, A. F., Dickersin, K., Dietz, K. C., Elimian, A., Grobman, W. A., Hodkinson, A., Maurel, K. A., McKenna, D. S., Mol, B. W., Moley, K., Mueller, J., Nassar, A., Norman, J. E., Norrie, J., O'Brien, J. M., Porcher, R., Rajaram, S., Rode, L., Rouse, D. J., Sakala, C., Schuit, E., Senat, M.-V., Sharif, S., Simmonds, M., Simpson, J. L., Smith, K., Tabor, A., Thom, E. A., van Os, M. A., Whitlock, E. P., Wood, S., & Walley, T.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-03
Volume
397
Issue
10280
Pages
1183-1194
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3138680213
Cited by
234
References
8
FWCI
8.76
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. https://app.cochat.ai/papers/10.1016/s0140-6736(21)00217-8
The paper
Stewart, L. A., Simmonds, M., Duley, L., Llewellyn, A., Sharif, S., Walker, R. A., Beresford, L., Wright, K., Aboulghar, M. M., Alfirevic, Z., Azargoon, A., Bagga, R., Bahrami, E., Blackwell, S. C., Caritis, S. N., Combs, C. A., Croswell, J. M., Crowther, C. A., Das, A. F., . . . Walley, T. (2021). Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials. The Lancet. https://doi.org/10.1016/s0140-6736(21)00217-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.